Survodutide
Also known as: BI 456906
Survodutide is a dual GLP-1 / glucagon receptor agonist co-developed by Boehringer Ingelheim and Zealand Pharma. NOT FDA-approved; received FDA Breakthrough Therapy Designation in 2024 for non-cirrhotic MASH with moderate/advanced fibrosis. Phase 3 ongoing (SYNCHRONIZE in obesity/T2DM; LIVERAGE and LIVERAGE-Cirrhosis in MASH).
Who's worth your money for Survodutide
Every current seller, ranked by independent evidence — Merit Score, latest COA purity, and live $/mg (size-normalized). Prices refresh daily. Rankings are never paid.
Top Merit pick
Highest Merit Score (90) of 6 scored sellers
$75.00 · 5mg
Best value
Lowest $/mg among scored sellers
$78.00 · 10mg · 99.4% purity
Average price
$21.22/mg
Sellers
24
45-day trend
+7.9%
17 of 24 sellers have a current price· 9 stale hidden· 2 unverified hidden
Top Merit pick
🇺🇸 Polaris Peptides90✓ verified at source · just now
$15.00/mg -29.3% vs avg$75.00
5mg
no purity- 🇺🇸 Peptidology89
✓ verified at source · just now
$8.00/mg -62.3% vs avg$79.99
10mg
- 🇺🇸 Ruo Bio88
✓ verified at source · just now
$9.80/mg -53.8% vs avg$98.00
10mg
- 🇺🇸 EZ Peptides85
✓ verified at source · just now
$7.80/mg -63.2% vs avg$78.00
10mg
- True Peptide82
✓ verified at source · just now
$12.00/mg -43.4% vs avg$120
10mg
- 🇭🇰 zztai Peptide Ltd42
✓ verified at source · just now
$25.70/mg +21.1% vs avg$257
10mg
no purity
Prices observed from public storefronts (last 24h), normalized to $/mg. "Evidence" is Merit's 0–100 Merit Score, derived only from observable verification evidence (methodology on /about); "Purity" is the latest independent COA. Some buy links are affiliate links — Merit may earn a commission at no extra cost to you, and where a vendor offers one, the code shown gets you a discount at their checkout. Affiliate status never affects price data, ranking, or the Merit Score (full policy on /disclosure). Research use only.
Watch Survodutide
Get one email when the market actually moves — no newsletter, no noise.
About Survodutide
CAS
2805997-46-8
Molecular formula
C192H289N47O61
Typical dose range
0.3–2.7 mg once weekly subcutaneous (clinical trials; Phase II/III dose-escalation)
Half-life
~6 days
COAs for Survodutide
25 third-party tests across 8 vendors. Each card links to the full report.
For
Survodutide
by Profound Aminos· batch Yellow Cap
For
Survodutide
by Real Peptides· batch Clear Cap/Purple Crimp
For
Suvrodutide
by Kimera Chems· batch KC-SVD-BLK1
For
Survodutide
by True Peptide· batch SURV-099-TPL
For
Survodutide
by Skye Peptides· batch SV25-12-001
For
Survodutide
by Ruo Bio· batch sur001
For
Survodutide
by Kimera Chems· batch KC-SVD-RED1
For
Survodutide
by Skye Peptides· batch SV25-06-001
For
Survodutide
by EZ Peptides· batch EZP-SURV1009082025-01
For
Survodutide
by EZ Peptides· batch EZP-SURV1009082025-01
For
Survodutide
by Profound Aminos· batch 2025-01-23
For
Survodutide
by Hydro Research Peptides· batch 2024-08-05
For
Survodutide
by Optima Supply· batch 2024-08-05
For
Survodutide
by Hydro Research Peptides· batch Survodutide-6028
For
Survodutide
by Optima Supply· batch Survodutide-6033
For
Survodutide
by Peptidology· batch 1671
For
Suvrodutide
by Kimera Chems· batch KC-SVD-RED1
Purity not on file
For
Survodutide
by Skye Peptides· batch SV25-12-001
Purity not on file
For
Survodutide
by Skye Peptides· batch SV25-12-001
Purity not on file
For
Survodutide
by Skye Peptides· batch SV25-06-001
Purity not on file
For
Survodutide
by Skye Peptides· batch SV25-06-001
Purity not on file
For
Survodutide
by Hydro Research Peptides· batch Survodutide-6028
Purity not on file
For
Survodutide
by Hydro Research Peptides· batch Survodutide-6028
Purity not on file
For
Survodutide
by optimasupply.is· batch Survodutide-6033
20 citations indexed for Survodutide
Study · 2026
Survodutide for Obesity in Chinese Adults: Phase 3 Randomized Trial Design and Baseline Characteristics (SYNCHRONIZE™-CN)
Introduction We aimed to describe the rationale, design, and overall baseline characteristics of the trial evaluating the efficacy, safety, and tolerability of survodutide in Chinese adults with overweight or obesity (SYNCHRONIZE™-CN, NCT06214741).
rct · 2026
Dual Glucagon and GLP-1 Receptor Agonist Survodutide Improves Biomarkers of Beta-Cell Function and Insulin Sensitivity in People With Type 2 Diabetes or Living With Overweight/Obesity
Aims This post hoc analysis evaluated the effect of survodutide on beta-cell function, insulin sensitivity, and glucose biomarkers in two phase 2 trial populations.
Study · 2026
Weight reduction-dependent/-independent effects of survodutide on liver endpoints: Mediation analysis of a phase 2 trial in MASH
Background and aims Survodutide was associated with improvements in liver-related endpoints in a phase 2 trial in MASH (NCT04771273). This post hoc mediation analysis evaluated the proportion of the direct treatment effect versus the indirect effect mediated by weight reduction.
review · 2026
Cardiovascular Effects of Glucagon Receptor Signaling Alone and Combined With Glucagon-Like Peptide-1 Receptor Signaling in Multiagonists: A Narrative Review With a Translational Focus
Cardio-kidney-metabolic diseases including obesity, metabolic dysfunction-associated liver disease, and type 2 diabetes have reached pandemic prevalence, fueling the search for new treatments for these conditions, given their associated complications, notably cardiovascular disease.
Study · 2026
Survodutide for the Treatment of Obesity Disease in Japanese Participants: Rationale, Design and Baseline Characteristics of the Phase 3 SYNCHRONIZE-JP Trial
Aims There is an unmet need for effective pharmacotherapy for obesity disease management in Japan. Survodutide is a novel glucagon receptor/glucagon-like peptide-1 receptor (GLP-1R) dual agonist with the potential to induce greater weight reductions than GLP-1R mono-agonists.
review · 2026
How does survodutide work? Plain language review of a potential new medication for obesity and liver disease
What is this review about? This review provides an overview of a medication called survodutide. Survodutide is not yet approved for use but is currently being tested to treat people living with obesity , as well as those living with MASH (metabolic dysfunction-associated steatohepatitis).